Email Alert RSS
Volume 14 Issue 3
May  2023
Turn off MathJax
Article Contents
Abstract
References
LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
Citation: LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
shu

Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors

  • 1.

    Department of Oncology, Chinese PLA Key Laboratory of Oncology, Ministry of Education Key Laboratory for Tumor Targeting Therapy and Antibody Drugs, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

  • 2.

    Graduate School, Chinese PLA General Hospital(Chinese PLA Medical School), Beijing 100853, China

  • 3.

    Department of Respiratory, the Eighth Medical Center of Chinese PLA General Hospital, Beijing 100853, China

  • 4.

    School of Medicine, Nankai University, Tianjin 300000, China

  • 5.

    Department of Nutrition, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

Funds: 

Special Key Project of National Health Commission of China GWJJ2021100304

More Information
  • Corresponding author:

    HU Yi, E-mail: huyi301zlxb@sina.com

  • Received Date: October 23, 2022
  • Accepted Date: December 11, 2022
  • Issue Publish Date: May 29, 2023
    Graphical Abstract
    • Abstract
  • In recent years, immunotherapy has become a new method for solid tumor treatment, and a large number of immune preparations have been developed and applied in clinical practice. Among them, immune checkpoint inhibitors (ICIs) are widely used, ushering in a new era for tumor treatment. In particular, cytotoxic T-lymphocyte-associated protein 4(CTLA-4), as a representative drug, enriches tumor immunotherapy methods and opens up a new treatment mode of dual immunotherapy. This article reviews the clinical application progress of CTLA-4 in the treatment of advanced solid tumors, with the hope of providing reference for immunotherapy of tumors.
    • FullText(HTML)
    • References (51)
  • [1]
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144: 646-674. DOI: 10.1016/j.cell.2011.02.013
    [2]
    Hanahan D. Hallmarks of Cancer: New Dimensions[J]. Cancer Discov, 2022, 12: 31-46. DOI: 10.1158/2159-8290.CD-21-1059
    [3]
    Ephraim R, Fraser S, Nurgali K, et al. Checkpoint Markers and Tumor Microenvironment: What Do We Know?[J]. Cancers (Basel), 2022, 14: 3788. DOI: 10.3390/cancers14153788
    [4]
    Maruhashi T, Sugiura D, Okazaki IM, et al. LAG-3: from molecular functions to clinical applications[J]. J Immunother Cancer, 2020, 8: e001014. DOI: 10.1136/jitc-2020-001014
    [5]
    Freed-Pastor WA, Lambert LJ, Ely ZA, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer[J]. Cancer Cell, 2021, 39: 1342-1360. DOI: 10.1016/j.ccell.2021.07.007
    [6]
    Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28[J]. Nature, 1993, 366: 76-79. DOI: 10.1038/366076a0
    [7]
    Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells[J]. J Exp Med, 1996, 183: 2533-2540. DOI: 10.1084/jem.183.6.2533
    [8]
    Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J]. Mol Cell Biol, 2005, 25: 9543-9553. DOI: 10.1128/MCB.25.21.9543-9553.2005
    [9]
    Ribas A. Releasing the Brakes on Cancer Immunotherapy[J]. N Engl J Med, 2015, 373: 1490-1492. DOI: 10.1056/NEJMp1510079
    [10]
    Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4[J]. J Exp Med, 2000, 192: 303-310. DOI: 10.1084/jem.192.2.303
    [11]
    Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4[J]. Science, 2011, 332: 600-603. DOI: 10.1126/science.1202947
    [12]
    Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discov, 2018, 8: 1069-1086. DOI: 10.1158/2159-8290.CD-18-0367
    [13]
    Hou TZ, Qureshi OS, Wang CJ, et al. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells[J]. J Immunol, 2015, 194: 2148-2159. http://pubmed.ncbi.nlm.nih.gov/25632005/
    [14]
    Pedicord VA, Montalvo W, Leiner IM, et al. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance[J]. Proc Natl Acad Sci USA, 2011, 108: 266-271. DOI: 10.1073/pnas.1016791108
    [15]
    Weber JS, Hamid O, Chasalow SD, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma[J]. J Immunother, 2012, 35: 89-97. DOI: 10.1097/CJI.0b013e31823aa41c
    [16]
    Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells[J]. Cancer Immunol Res, 2013, 1: 32-42. DOI: 10.1158/2326-6066.CIR-13-0013
    [17]
    Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers[J]. Clin Cancer Res, 2019, 25: 1233-1238. DOI: 10.1158/1078-0432.CCR-18-0762
    [18]
    Felix J, Lambert J, Roelens M, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response[J]. Oncoimmunology, 2016, 5: 1136045. DOI: 10.1080/2162402X.2015.1136045
    [19]
    Gubin MM, Esaulova E, Ward JP, et al. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy[J]. Cell, 2018, 175: 1014-1030. DOI: 10.1016/j.cell.2018.09.030
    [20]
    Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38: 255. DOI: 10.1186/s13046-019-1259-z
    [21]
    Willsmore ZN, Coumbe B, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action[J]. Eur J Immunol, 2021, 51: 544-556. DOI: 10.1002/eji.202048747
    [22]
    McDermott D, Haanen J, Chen TT, et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase Ⅲ trial (MDX010-20)[J]. Ann Oncol, 2013, 24: 2694-2698. DOI: 10.1093/annonc/mdt291
    [23]
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2015, 16: 522-530. DOI: 10.1016/S1470-2045(15)70122-1
    [24]
    Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19: 1480-1492. DOI: 10.1016/S1470-2045(18)30700-9
    [25]
    Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378: 1277-1290. DOI: 10.1056/NEJMoa1712126
    [26]
    Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase Ⅲ CheckMate 227 trial[J]. Eur J Cancer, 2019, 116: 137-147. DOI: 10.1016/j.ejca.2019.05.008
    [27]
    Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial[J]. J Thorac Oncol, 2022, 17: 289-308. DOI: 10.1016/j.jtho.2021.09.010
    [28]
    Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22: 198-211. DOI: 10.1016/S1470-2045(20)30641-0
    [29]
    Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2021, 397: 375-386. DOI: 10.1016/S0140-6736(20)32714-8
    [30]
    Kudo M. Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma[J]. Liver Cancer, 2022, 11: 87-93. DOI: 10.1159/000523702
    [31]
    Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017, 18: 1182-1191. DOI: 10.1016/S1470-2045(17)30422-9
    [32]
    Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6: e204564. DOI: 10.1001/jamaoncol.2020.4564
    [33]
    朱军, 黄美金, 陈宏. 进展期胃癌免疫治疗的研究进展[J]. 癌症进展, 2022, 20: 1189-1193. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202212021.htm
    [34]
    Tarhini AA, Kang N, Lee SJ, et al. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis[J]. J Immunother Cancer, 2021, 9: e002535. DOI: 10.1136/jitc-2021-002535
    [35]
    Govindan R, Szczesna A, Ahn MJ, et al. Phase Ⅲ Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2017, 35: 3449-3457. DOI: 10.1200/JCO.2016.71.7629
    [36]
    Kang S, Wang X, Zhang Y, et al. First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis[J]. Front Oncol, 2021, 11: 740091.
    [37]
    Yu J, Ma S, Tian S, et al. Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes[J]. Front Cell Dev Biol, 2021, 9: 700553. DOI: 10.3389/fcell.2021.700553
    [38]
    Cedres S, Felip E. 3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma[J]. Ann Oncol, 2022, 33: 457-459. DOI: 10.1016/j.annonc.2022.03.004
    [39]
    Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer[J]. Cancers (Basel), 2022, 14: 1054. DOI: 10.3390/cancers14041054
    [40]
    Weiss SA, Kluger H. CheckMate-067: Raising the Bar for the Next Decade in Oncology[J]. J Clin Oncol, 2022, 40: 111-113. http://pubmed.ncbi.nlm.nih.gov/34855466/
    [41]
    Zhang X, Wu T, Cai X, et al. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities[J]. Front Immunol, 2022, 13: 795972. DOI: 10.3389/fimmu.2022.795972
    [42]
    Cavillon A, Pouessel D, Houédé N, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase Ⅲ Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials[J]. Eur Urol, 2023, 25: S0302-2838(23)02619-2.
    [43]
    Owonikoko TK, Park K, Govindan R, et al. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451[J]. J Clin Oncol, 2021, 39: 1349-1359. DOI: 10.1200/JCO.20.02212
    [44]
    Peters S, Pujol JL, Dafni U, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy-results from the randomised phase Ⅱ ETOP/IFCT 4-12 STIMULI trial[J]. Ann Oncol, 2022, 33: 67-79. DOI: 10.1016/j.annonc.2021.09.011
    [45]
    Mariniello A, Novello S, Scagliotti GV, et al. Double immune checkpoint blockade in advanced NSCLC[J]. Crit Rev Oncol Hematol, 2020, 152: 102980. DOI: 10.1016/j.critrevonc.2020.102980
    [46]
    Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6: 661-674. DOI: 10.1001/jamaoncol.2020.0237
    [47]
    Boyer M, Şendur M, Rodríguez-Abreu D, et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase Ⅲ KEYNOTE-598 Study[J]. J Clin Oncol, 2021, 39: 2327-2338. DOI: 10.1200/JCO.20.03579
    [48]
    Lee JY, Lee HT, Shin W, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy[J]. Nat Commun, 2016, 7: 13354. DOI: 10.1038/ncomms13354
    [49]
    He M, Chai Y, Qi J, et al. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies[J]. Oncotarget, 2017, 8: 67129-67139. DOI: 10.18632/oncotarget.18004
    [50]
    Ramagopal UA, Liu W, Garrett-Thomson SC, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab[J]. Proc Natl Acad Sci USA, 2017, 114: E4223-E4232. http://europepmc.org/articles/PMC5448203/pdf/pnas.201617941.pdf
    [51]
    左乔竹, 覃文新. CTLA-4和PD-1信号通路在实体瘤治疗中的研究进展[J]. 生命科学, 2017, 29: 713-721. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX201708002.htm
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views PDF downloads Cited by()
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close

      【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！